The ASCO Post: Predictive and Prognostic Biomarkers in Immunotherapy: Recent Episodes
Harborside
Predictive and Prognostic Biomarkers in Immunotherapy
Moderator: Vamsi Velcheti, MD, Associate Professor, Director, Thoracic Oncology Program NYU Langone- Laura and Isaac Perlmutter Cancer Center, New York
Faculty: Hossein Borghaei, DO, MS, Chief, Thoracic Medical Oncology, Co-Leader, Thoracic Cancer Service Line, Fox Chase Cancer Center, Philadelphia; and David Rimm, MD, PhD, Professor of Pathology and of Medicine (Medical Oncology); Director of Pathology Tissue Services; Director of Translational Pathology, Yale New Haven Hospital, New Haven
Citing the recent landmark tumor-agnostic approval of pembrolizumab for patients with microsatellite instability-high (MSI-H)/deficient DNA mismatch repair (dMMR) tumors and the approval of nivolumab/ipilimumab MSI-H/dMMR colorectal cancer, Vamsi Velcheti, MD, and Hossein Borghaei, DO, MS, discuss the role of MSI-H and dMMR testing in immunotherapy treatment selection.
Instructions for CME credit:
If you would like to earn credit, you must take the pre-test first by visiting https://education.annenberg.net/5680-2.
To finish earning credit, you must take the post-test by visiting https://education.annenberg.net/node/9440/take/1.
Vamsi Velcheti, MD, and David Rimm, MD, PhD, discuss the recent clinical trials that studied tumor mutation burden (TMB) as a biomarker and the mechanisms behind why tumors with high TMB respond to immunotherapy.
Instructions for CME credit:
If you would like to earn credit, you must take the pre-test first by visiting https://education.annenberg.net/5680-4.
To finish earning credit, you must take the post-test by visiting https://education.annenberg.net/node/9461/take/1.
Vamsi Velcheti, MD, and David Rimm, MD, PhD, discuss the high number of recent programmed death-lingad 1 (PD-L1) inhibitor approvals and the need to harmonize the various diagnostic assay developments across the supporting clinical trials. Dr. Rimm notes the important difference between companion diagnostics, which must be used to test PD-L1 levels before prescribing a drug, and complementary diagnostics, which the FDA recommends using prior to prescribing the PD-L1 inhibitor.
Instructions for CME credit:
If you would like to earn credit, you must take the pre-test first by visiting https://education.annenberg.net/5680-3.
To finish earning credit, you must take the post-test by visiting https://education.annenberg.net/node/9452/take/1.
Vamsi Velcheti, MD, and Hossein Borghaei, DO, MS, discuss challenges in using programmed death ligand 1 (PD-L1) and tumor mutation burdent (TMB) as biomarkers to determine which patients will or won’t respond to immunotherapy with a checkpoint inhibitor as well as whether biomarkers exist to identify which patients will experience adverse events from immunotherapies.
Instructions for CME credit:
If you would like to earn credit, you must take the pre-test first by visiting https://education.annenberg.net/5680-1.
To finish earning credit, you must take the post-test by visiting https://education.annenberg.net/node/9431/take/1.